Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cockayne syndrome A protein (CSA) is encoded by the ERCC8 gene located on chromosome 5q12.1. The CSA protein is a DNA repair factor that functions as a substrate-recognition component of the DCX (DDB1-CUL4-X-box) E3 ubiquitin–protein ligase complex. Its main role is in transcription-coupled nucleotide excision repair (TC-NER), where it helps remove RNA polymerase II-blocking DNA lesions from actively transcribed genes. Mutations in the ERCC8 gene impair this DNA repair process, leading to Cockayne syndrome type A—a rare, fatal, autosomal recessive neurodegenerative disorder marked by growth failure, developmental delays, photosensitivity, and premature aging. ERCC8 mutations are not associated with increased cancer risk.
Not applicable for drug targeting, as this molecule is not currently a therapeutic target; its role is intrinsic in DNA repair
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cockayne syndrome A protein (CSA).